Recent Quotes
My Watchlist
Indicators
EL&P Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Harmony Biosciences Holdings, Inc. - Common Stock (NQ:HRMY)

37.58 -1.20 (-3.09%)
Streaming Delayed Price Updated: 2:39 PM EDT, Aug 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Harmony Biosciences Holdings, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Harmony Biosciences Holdings (NASDAQ:HRMY) Emerges as a Prime GARP Investment ↗
Via Chartmill
News headline image
Harmony Biosciences to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026
From Harmony Biosciences Holdings, Inc.
Via Business Wire
News headline image
Harmony Biosciences Chief Financial Officer Sells Shares Again After Previous Exit From Company Equity ↗
This top executive at Harmony Biosciences previous sold all of his direct shares in the company in early January 2026. But towards the end of the month, some options and restricted stock units vested,... 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Harmony Biosciences' CFO Sells All of His Insider Shares, Worth $752,800 ↗
This bioscience company has had promising financials, yet one of its top executives exited his entire direct equity ownership in mid-January 2026. 
Via The Motley Fool
Topics Regulatory Compliance
Harmony Biosciences Holdings (NASDAQ:HRMY) Combines Strong Fundamentals with Bullish Technical Setup ↗
Via Chartmill
Harmony Biosciences Holdings (NASDAQ:HRMY) Embodies the Affordable Growth Strategy ↗
Via Chartmill
Harmony Biosciences Holdings (NASDAQ:HRMY) Presents a Compelling Value and Quality Investment Case ↗
Via Chartmill
News headline image
Earnings Scheduled For November 4, 2025 ↗
 
Via Benzinga
News headline image
Harmony Biosciences' CFO Sells All of Her Insider Shares, Worth $752,800 ↗
This bioscience company has had promising financials, yet one of its top executives exited her entire direct equity ownership in mid-January 2026. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
How Harmony Biosciences Can Prove Its Skeptics Wrong ↗
The biotech company is looking for multiple successes in the coming years. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Harmony Biosciences' Sales and Profits Have Soared. Why Hasn't Its Stock Followed? ↗
Some investors haven't gotten answers to their questions about the biotech stock's past and future. 
Via The Motley Fool
Topics Initial Public Offering Intellectual Property
News headline image
I Was Shocked to Find This Value-Priced Biotech Growth Stock ↗
But deciding if it's a good buy takes a little more looking. 
Via The Motley Fool
News headline image
Earnings Preview For Harmony Biosciences ↗
 
Via Benzinga
Harmony Biosciences Raises Full-Year Revenue Guidance Ahead Of Earnings: Why Are Wakix Franchise Numbers Crucial? ↗
Via Stocktwits
News headline image
Harmony Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference
From Harmony Biosciences Holdings, Inc.
Via Business Wire
News headline image
Rhythm Pharmaceuticals Faces Gravity: FDA Delays and Valuation Pressures Cool 2025’s Biotech Darling
As the final trading days of 2025 wind down, Rhythm Pharmaceuticals (Nasdaq: RYTM) finds itself at a critical crossroads. After a meteoric rise that saw the stock gain over 100% through the first three... 
Via MarketMinute
Topics ETFs Economy World Trade
News headline image
Harmony Biosciences Holdings (NASDAQ:HRMY) Emerges as a Prime Growth at a Reasonable Price (GARP) Candidate ↗
Harmony Biosciences (HRMY) exemplifies Growth at a Reasonable Price (GARP) with strong sales growth, robust profitability, and a solid financial base, all at a compelling valuation. 
Via Chartmill
News headline image
Beacon Biosignals Announces Partnership with Harmony Biosciences to Advance Objective Clinical Endpoints in Hypersomnia Conditions Through Quantitative EEG
From Beacon Biosignals
Via GlobeNewswire
News headline image
Harmony Biosciences Holdings (NASDAQ:HRMY) Presents a Compelling Value Investment Case ↗
Harmony Biosciences (HRMY) presents a classic value investing case with strong profitability, a healthy balance sheet, and solid growth—all at a compellingly low valuation. 
Via Chartmill
News headline image
Harmony Biosciences Presents Clinically Meaningful Open-Label Extension Study Effectiveness Data for EPX-100 in Dravet Syndrome
From Harmony Biosciences Holdings, Inc.
Via Business Wire
News headline image
Harmony Biosciences to Present New Open-Label Extension Data from Phase 3 ARGUS Trial at the 2025 American Epilepsy Society Annual Meeting
From Harmony Biosciences Holdings, Inc.
Via Business Wire
News headline image
Harmony Biosciences Holdings (NASDAQ:HRMY) Presents a Compelling Case for Growth at a Reasonable Price ↗
Harmony Biosciences (HRMY) is a top GARP stock with strong growth, stellar profitability, and a surprisingly cheap valuation. A compelling growth at a reasonable price pick. 
Via Chartmill
News headline image
Harmony Biosciences Announces Positive Results From the Pivotal Bioequivalence Study for Pitolisant Gastro-Resistant Formulation
From Harmony Biosciences Holdings, Inc.
Via Business Wire
News headline image
Harmony Biosciences Announces Initiation of First-In-Human Study With Potential Best-In-Class Orexin 2 Receptor Agonist (BP1.15205) for Central Disorders of Hypersomnolence
From Harmony Biosciences Holdings, Inc.
Via Business Wire
News headline image
Harmony Biosciences to Participate in Upcoming Investor Conferences
From Harmony Biosciences
Via Business Wire
News headline image
Harmony Biosciences Holdings (NASDAQ:HRMY) Appears Undervalued with Strong Fundamentals ↗
Harmony Biosciences (HRMY) appears undervalued with a low P/E ratio, strong profitability, and impressive growth, suggesting a potential market opportunity. 
Via Chartmill
News headline image
Harmony Biosciences Holdings (NASDAQ:HRMY) Beats Q3 2025 Estimates Despite Muted Market Reaction ↗
Harmony Biosciences Q3 2025 earnings beat estimates with strong WAKIX growth. Despite the beat, stock dipped slightly in pre-market trading. 
Via Chartmill
Topics Earnings
News headline image
Harmony Biosciences Reports Strong Q3 2025 Financial Results; Recently Raised 2025 Revenue Guidance to $845-$865M
From Harmony Biosciences Holdings, Inc.
Via Business Wire
News headline image
Harmony Biosciences Holdings (NASDAQ:HRMY): A Prime GARP Investment with Strong Growth and a Reasonable Price ↗
Harmony Biosciences (HRMY) offers strong growth at a reasonable price. With high EPS growth, robust profitability, and a low P/E ratio, it's a top GARP stock. 
Via Chartmill
News headline image
Q3 2025 Earnings Season: A Market Navigating AI's Ascent Amidst Economic Shifts
The curtain has largely fallen on the Q3 2025 earnings season, revealing a financial landscape characterized by robust corporate performance, particularly in the technology and financial sectors,... 
Via MarketMinute
Topics Artificial Intelligence Economy Fraud
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.